Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash & Current Investments: 2010-2021

Historic Cash & Current Investments for Neurocrine Biosciences (NBIX) over the last 12 years, with Sep 2021 value amounting to $765.9 million.

  • Neurocrine Biosciences' Cash & Current Investments fell 18.93% to $765.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was $3.3 billion, marking a year-over-year decrease of 0.19%. This contributed to the annual value of $804.2 million for FY2020, which is 19.94% up from last year.
  • According to the latest figures from Q3 2021, Neurocrine Biosciences' Cash & Current Investments is $765.9 million, which was down 13.45% from $884.9 million recorded in Q2 2021.
  • Neurocrine Biosciences' Cash & Current Investments' 5-year high stood at $948.3 million during Q2 2020, with a 5-year trough of $235.6 million in Q1 2017.
  • Moreover, its 3-year median value for Cash & Current Investments was $771.7 million (2020), whereas its average is $770.7 million.
  • Per our database at Business Quant, Neurocrine Biosciences' Cash & Current Investments tumbled by 38.25% in 2017 and then spiked by 95.47% in 2018.
  • Over the past 5 years, Neurocrine Biosciences' Cash & Current Investments (Quarterly) stood at $515.9 million in 2017, then climbed by 26.16% to $650.9 million in 2018, then climbed by 3.01% to $670.5 million in 2019, then grew by 19.94% to $804.2 million in 2020, then dropped by 18.93% to $765.9 million in 2021.
  • Its last three reported values are $765.9 million in Q3 2021, $884.9 million for Q2 2021, and $873.7 million during Q1 2021.